中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
Chinese Journal of Biochemical Pharmaceutics
2015年
9期
115-117
,共3页
氯吡格雷%进展性缺血性脑卒中%颈部血管狭窄度%血浆纤维蛋白原
氯吡格雷%進展性缺血性腦卒中%頸部血管狹窄度%血漿纖維蛋白原
록필격뢰%진전성결혈성뇌졸중%경부혈관협착도%혈장섬유단백원
clopidogrel%stroke in progression%neck vascular stenosis%plasma fibrinogen
目的:研究氯吡格雷治疗对进展性缺血性脑卒中( stroke in progression,SIP)患者恢复期颈部血管狭窄度、血浆纤维蛋白原( fibrinogen,FIB)变化影响。方法选取2014年3月到2015年3月收治的SIP患者80例,按照随机数字表法将患者分为研究组和对照组,每组40例,对照组给予常规治疗,研究组在常规治疗的基础上给予氯吡格雷,应用颈动脉彩色多普勒评价颈部血管狭窄度,应用美国国立卫生研究院卒中量表( NIHSS)和日常生活能力评分( ADL)评价患者神经功能和生活能力,测量2组FIB和超敏C反应蛋白( hs-CRP)水平,比较2组不良反应情况。结果治疗前2组颈总动脉、颈内动脉、颈外动脉内径宽度比较,差异无统计学意义,治疗后2组颈总动脉、颈内动脉、颈外动脉内径宽度均显著增加,且研究组宽于对照组(P<0.05);治疗前2组NIHSS评分和ADL评分比较无统计学意义,治疗后2组NIHSS评分和ADL评分均显著改善,且研究组优于对照组( P<0.05);2组治疗前FIB和hs-CRP比较,差异无统计学意义,治疗后2组FIB和hs-CRP水平显著降低,研究组显著低于对照组(P<0.05);2组不良反应比较,差异无统计学意义。结论氯吡格雷治疗SIP患者恢复期能显著改善患者神经功能,改善颈部血管狭窄度,降低FIB水平。
目的:研究氯吡格雷治療對進展性缺血性腦卒中( stroke in progression,SIP)患者恢複期頸部血管狹窄度、血漿纖維蛋白原( fibrinogen,FIB)變化影響。方法選取2014年3月到2015年3月收治的SIP患者80例,按照隨機數字錶法將患者分為研究組和對照組,每組40例,對照組給予常規治療,研究組在常規治療的基礎上給予氯吡格雷,應用頸動脈綵色多普勒評價頸部血管狹窄度,應用美國國立衛生研究院卒中量錶( NIHSS)和日常生活能力評分( ADL)評價患者神經功能和生活能力,測量2組FIB和超敏C反應蛋白( hs-CRP)水平,比較2組不良反應情況。結果治療前2組頸總動脈、頸內動脈、頸外動脈內徑寬度比較,差異無統計學意義,治療後2組頸總動脈、頸內動脈、頸外動脈內徑寬度均顯著增加,且研究組寬于對照組(P<0.05);治療前2組NIHSS評分和ADL評分比較無統計學意義,治療後2組NIHSS評分和ADL評分均顯著改善,且研究組優于對照組( P<0.05);2組治療前FIB和hs-CRP比較,差異無統計學意義,治療後2組FIB和hs-CRP水平顯著降低,研究組顯著低于對照組(P<0.05);2組不良反應比較,差異無統計學意義。結論氯吡格雷治療SIP患者恢複期能顯著改善患者神經功能,改善頸部血管狹窄度,降低FIB水平。
목적:연구록필격뢰치료대진전성결혈성뇌졸중( stroke in progression,SIP)환자회복기경부혈관협착도、혈장섬유단백원( fibrinogen,FIB)변화영향。방법선취2014년3월도2015년3월수치적SIP환자80례,안조수궤수자표법장환자분위연구조화대조조,매조40례,대조조급여상규치료,연구조재상규치료적기출상급여록필격뢰,응용경동맥채색다보륵평개경부혈관협착도,응용미국국립위생연구원졸중량표( NIHSS)화일상생활능력평분( ADL)평개환자신경공능화생활능력,측량2조FIB화초민C반응단백( hs-CRP)수평,비교2조불량반응정황。결과치료전2조경총동맥、경내동맥、경외동맥내경관도비교,차이무통계학의의,치료후2조경총동맥、경내동맥、경외동맥내경관도균현저증가,차연구조관우대조조(P<0.05);치료전2조NIHSS평분화ADL평분비교무통계학의의,치료후2조NIHSS평분화ADL평분균현저개선,차연구조우우대조조( P<0.05);2조치료전FIB화hs-CRP비교,차이무통계학의의,치료후2조FIB화hs-CRP수평현저강저,연구조현저저우대조조(P<0.05);2조불량반응비교,차이무통계학의의。결론록필격뢰치료SIP환자회복기능현저개선환자신경공능,개선경부혈관협착도,강저FIB수평。
Objective To study effect of clopidogrel on neck blood vessel stenosis and plasma fibrinogen ( FIB ) in patients with stroke in progression(SIP).Methods 80 cases with SIP were selected from March 2014 to March 2015, they were divided into study group and control group according to the random number table method, 40 cases in each group, the control group was received conventional treatment, the study group was given clopidogrel on the basis of conventional treatment, evaluation of neurological function and living ability of patients with Stroke Scale (NIHSS) and daily living ability score ( ADL) , carotid artery stenosis were measured by color Doppler, the levels of FIB and C reactive protein ( hs-CRP) in two groups were also measured, adverse reactions in the two groups were compared.Results Carotid artery, internal carotid artery, external carotid artery diameter before treatment between two groups were no statistical significance,which all increased after treatment, and the study group was wider than the control group, the difference was statistically significant (P <0.05);NIHSS score and ADL score before the treatment between two groups was no statistical significance.NIHSS score and ADL score after treatment between two groups were significant improved, and the study group was better than the control group, the difference was statistically significant (P<0.05); FIB and hs-CRP before the treatment between two groups was no statistical significance, FIB and hs-CRP levels after treatment between two groups were significantly reduced, the study group was significantly lower than the control group, the difference was statistically significant (P<0.05); the adverse reactions of the two groups were not statistically significant.Conclusion Clopidogrel can significantly improve the neurological function, improve the degree of cervical vascular stenosis, reduce the level of FIB for SIP patients in recovery period.